Table 1.
Characteristics of documented male patients with advanced prostate cancer (total number = 1273)
| Demographic data: mean (minimum, maximum) | |
|---|---|
| Age (years) | 75 (50, 97) |
| Weight (kg) | 81 (45, 160) |
| Height (cm) | 175 (157, 198) |
| Diagnosis/findings: mean | |
| Time since first diagnosis (months) | 33 |
| Biopsy: Number of cores | 8.2 |
| Number of positive cores | 4.5 |
| cT1-2, % | 44 |
| cT3-4, % | 32 |
| M+, % | 20 |
| Gleason grade (1-5) | 3.4 |
| Gleason sum (2-10) | 6.8 |
| Therapy with GnRH analogues: number of patients (%) | |
| First-time treatment | 610 (48) |
| Pre-treatment* | 652 (51) |
| 3 monthly leuprolide acetate | 210 (32.2) |
| Leuprolide acetate, Takeda Pharmaceutical | 168 (25.8) |
| Goserelin acetate, AstraZenca | 107 (16.4) |
| Buserelin acetate, Sanofi-Aventis | 97 (14.9) |
| 1 monthly leuprolide acetate | 27 (4.1) |
| Leuprorelin acetate, Takeda Pharmaceutical | 21 (3.2) |
| Other drugs | 22 (3.4) |
| Missing data | 15 (2.3) |
*Percentage refers to patients with change of therapy (n = 652). Total n = 667 includes multiple namings: single n = 637; 2-fold: n = 15